anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

199,321-199,380 of 319,975

filter-aware
34
The slide includes both Gross Debt/EBITDA and Net Debt/EBITDA metrics.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations Beat · Financials1 hit
35
The chart highlights a 54% five-year annualized TSR for Crocs, significantly outperforming the benchmarks.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations Beat · Financials1 hit
36
The slide is purely visual, serving as a section divider or appendix cover.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations 1 hit
37
Standard financial reporting appendix slide.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations 1 hit
38
Includes specific footnotes explaining adjustments for distribution centers, HEYDUDE inventory fair value step-up, and Russia inventory reserves.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations 1 hit
39
Includes footnotes explaining specific adjustments like HEYDUDE acquisition costs and Russia operations shutdown.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations 1 hit
40
The slide provides a detailed breakdown of adjustments to cost of sales and SG&A expenses to arrive at non-GAAP figures.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations 1 hit
41
Includes footnotes regarding Non-GAAP adjustments and intra-entity IP transfers.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations 1 hit
42
The slide provides a detailed breakdown of adjustments to GAAP net income and share counts to arrive at Non-GAAP EPS.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations 1 hit
43
Includes detailed footnotes explaining the nature of the adjustments and the company's policy on non-GAAP reporting.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations 1 hit
44
Contains two separate tables for different brands with footnotes explaining the adjustments.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations 1 hit
45
Includes adjustments for Russia operations and other items.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations 1 hit
46
The slide contains two separate tables for different brands and time periods.Crocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations 1 hit
47
Crocs | Investor Presentation Deck | 47 slidesCrocs | Investor Presentation Deck | 47 slides · Crocs
Pitch deck Investor relations 1 hit
01
Slide 1
The slide uses a linguistic metaphor to define the brand identity.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
02
Text-heavy legal/disclaimer slide with multi-paragraph fine print and a subtle barcode-like background pattern. No data, charts, or imagery beyond the headline and prose.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
03
Dare Bioscience | Investor Presentation Deck | 54 slidesDare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
04
The slide uses a contrast between the low research/pipeline investment (left) and the high market impact/purchasing power (right) to argue for efficiency.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
05
The slide uses a comparative framework to show market potential by citing historical peak revenues of successful drugs.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Beat · Market Size1 hit
06
The slide uses a grid-like layout to organize product candidates by category.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
07
The slide uses a numbered list for the thesis points and a separate callout box for milestones.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
08
The slide uses a Gantt-chart style visualization to show the progress of multiple drug candidates across clinical phases.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
09
Includes specific financial terms of the collaboration and regulatory milestones.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
10
The slide uses a structured layout to compare three distinct product pipelines.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
11
The slide uses a two-tier layout to distinguish between Phase 1 and Preclinical development stages.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
12
The slide uses a process-like flow to connect internal strengths to external market validation.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
13
The slide uses a standard team/board layout with a logo cloud at the bottom to establish credibility.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Beat · Team1 hit
14
Dare Bioscience | Investor Presentation Deck | 54 slidesDare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
15
The slide uses a simple list format to communicate upcoming program milestones.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
16
Slide 16 of a pitch deck.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
17
The slide uses a structured comparison format to frame the medical problem and the proposed solution.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
18
Mentions Organon as the commercial partner leveraging the NEXPLANON sales team.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
The slide highlights a key partnership milestone and the associated financial structure (upfront payment and potential milestones).Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
20
Standard pharmaceutical ISI (Important Safety Information) slide.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
This is a regulatory disclosure slide regarding drug safety in specific patient demographics.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
The slide uses a high-contrast design with a large yellow circle on the left and a deep blue background, emphasizing the product name and its core value proposition.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
23
Includes a line chart of population projections and three circular callouts detailing specific product sales.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
24
The slide uses a tree-like diagram to segment the total addressable market into specific contraceptive user groups.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
25
The slide uses a vertical axis to represent effectiveness, positioning the company's product as a bridge between traditional barrier methods and the Copper IUD.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
The slide uses a comparison table structure to map desired product features to specific Ovaprene design attributes.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
27
Includes details on milestone payments, royalties, and strategic support from Bayer.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
28
Includes a testimonial quote from a Bayer executive.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
29
Includes a data table comparing baseline PCT results with Ovaprene PCT results.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
30
The slide highlights the lack of existing FDA-approved therapies for FSAD.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
31
Uses a visual inequality symbol to emphasize the distinction between FSAD and HSDD.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
32
The slide uses a double-bordered box design to separate academic meta-analysis from commercial market research estimates.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
33
The slide uses a light blue callout box to group the product benefits and highlights the lack of current FDA-approved treatments for FSAD.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
34
The slide outlines the methodology and goals of a clinical trial, specifically mentioning the RESPOND study.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
35
The slide uses clinical trial data to justify the pivot to a topical delivery mechanism.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
36
Includes a table of pharmacokinetic parameters and a line chart showing plasma concentration over time.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
37
Study design is a small N=6 crossover trial.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
38
Dare Bioscience | Investor Presentation Deck | 54 slidesDare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
39
The slide uses a side-by-side comparison layout to contrast the biological route with the technical solution.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
40
The slide frames the market opportunity and clinical need for a non-oral hormone therapy.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
41
The slide highlights statistically significant improvements (p<0.01) across multiple clinical endpoints.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
42
The slide details the specific regulatory strategy for a pharmaceutical product, focusing on the 505(b)(2) pathway.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
43
Dare Bioscience | Investor Presentation Deck | 54 slidesDare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
44
The slide uses a grid-based layout to organize product candidates by development stage (Phase 1 vs Preclinical).Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
45
The slide highlights the clinical need for non-daily dosing progesterone delivery systems.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
46
The slide highlights a specific clinical need for breast cancer survivors.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit